NCT06982066 Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention
| NCT ID | NCT06982066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Connecticut Children's Medical Center |
| Condition | Pediatric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-02-10 |
| Primary Completion | 2029-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-02-10 with a primary completion date of 2029-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching goal is to develop and demonstrate proof-of-concept of ReSPECT (Reproductive and Sexual Health Patient Education and Communication Tool), a multi-modal communication intervention to improve adolescent and young adult (AYA)- clinician sexual and reproductive health (SRH) communication in the outpatient oncology clinic setting.
Eligibility Criteria
Inclusion Criteria Adolescent and Young Adult Oncology Patients In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Be aged 15-25 years old at time of enrollment. 2. Have a cancer diagnosis and currently be on cancer-directed therapy with at least one of the following: 1. Chemotherapy: any anticancer drug to treat the cancer diagnosis, including immunotherapy. 2. Radiotherapy: any radiotherapy to treat the cancer diagnosis. 3. Surgery: any surgery to remove cancer including partial of total resections. Biopsies are not considered surgery. 3. Be greater than or equal to 2 months from diagnosis/initiation of therapy, whichever occurred later. 4. Be able to speak and read English 5. Have permission to participate from a member of the patient's primary oncology team. 6. Provision to sign and date the consent/assent form. 7. Active study participation of primary oncology clinician 8. Patient must have primary oncology care at Connecticut Children's Center for Cancer \& Blood Disorders of Children's Hospital Los Angeles Cancer \& Blood Disease Institute Exclusion Criteria An individual who meets and of the following criteria will be excluded from participation in this study: 1. Not currently on cancer-directed therapy. 2. Unable to speak and read English. 3. Insufficient cognitive functioning to complete study measures (as determined by a member of the patient's primary oncology team) Pediatric Oncology Clinicians 1\. Be a pediatric oncology physician, clinical fellow, or advanced practice provider (including nurse practitioners and physician assistants) that provides clinical care for AYA patients with cancer
Contact & Investigator
Natasha Frederick, MD, MPH
PRINCIPAL INVESTIGATOR
nfrederick@connecticutchildrens.org
Frequently Asked Questions
Who can join the NCT06982066 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 25 Years, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06982066 currently recruiting?
Yes, NCT06982066 is actively recruiting participants. Contact the research team at nfrederick@connecticutchildrens.org for enrollment information.
Where is the NCT06982066 trial being conducted?
This trial is being conducted at Hartford, United States.
Who is sponsoring the NCT06982066 clinical trial?
NCT06982066 is sponsored by Connecticut Children's Medical Center. The principal investigator is Natasha Frederick, MD, MPH at nfrederick@connecticutchildrens.org. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.